Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) Return on Capital Employed (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Return on Capital Employed for 10 consecutive years, with 0.36% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Capital Employed rose 9.0% year-over-year to 0.36%, compared with a TTM value of 0.36% through Dec 2025, up 9.0%, and an annual FY2025 reading of 0.33%, up 16.0% over the prior year.
  • Return on Capital Employed was 0.36% for Q4 2025 at Spyre Therapeutics, up from 0.45% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 2.56% in Q2 2023 and bottomed at 1.61% in Q1 2023.
  • Average Return on Capital Employed over 5 years is 0.58%, with a median of 0.6% recorded in 2021.
  • The sharpest move saw Return on Capital Employed soared 367bps in 2023, then tumbled -292bps in 2024.
  • Year by year, Return on Capital Employed stood at 0.66% in 2021, then tumbled by -92bps to 1.27% in 2022, then rose by 21bps to 1.0% in 2023, then skyrocketed by 55bps to 0.45% in 2024, then grew by 21bps to 0.36% in 2025.
  • Business Quant data shows Return on Capital Employed for SYRE at 0.36% in Q4 2025, 0.45% in Q3 2025, and 0.45% in Q2 2025.